☢️Radiopharma Breaking News☢️ Trials, Approvals, Launches, FDA, Science, M&A, CDMOs, Isotopes
Indianapolis, IN
Joined October 2026
- Tweets14
- Following56
- Followers4
- Likes0
☢️ BREAKING: Molecular Partners pivots to a dedicated radiopharma company
Its lead Radio-DARPin MP0712 (212Pb, DLL3) cleared dose level 1 with no dose-limiting events — a whole company, re-aimed at one half-life.
da.gd/doN87B
☢️ BREAKING ☢️
Eckert & Ziegler gets GMP certificate for Actinium-225 production in Germany Ac-225 supply just got a real factory stamp — alpha therapies need isotopes, not just ideas.
da.gd/JXlj
☢️ BREAKING: FTC Second Request extends Lantheus-Curium $8B merger review
Longer half-life for the deal: HSR clock runs 30 days past compliance, close still H1 2027.
ITM COMPETE at #EANM2026: higher 177Lu-edotreotide tumor dose linked to higher response, ORR 12% → 64%
☢️ BREAKING: FDA lets Alpha Tau double its Alpha DaRT brain-tumor trial
REGAIN goes 10 → 20 patients, adding PFS and quality-of-life endpoints. Interim safety data lands at SNO in November.
da.gd/oaetk9
☢️ BREAKING: Full-Life's FL-261 posts first-in-human imaging data at EANM
c-MET imaging in lung cancer, clean safety — and the Ac-225 therapy version is already IND-cleared. Top Rated Oral OP-442. #EANM2026
da.gd/JTON1Y
Telix + Ekalia to produce astatine-211 in the U.S., starting at RLS Trevose near Philadelphia
At-211 can't be stockpiled — so Telix is building the tap at home, with priority access for TLX102-Tx.
AtomVie taps Jubilant Radiopharma for U.S. clinical-trial logistics and last-mile distribution
Making the drug is half the battle — with a short half-life, the other half is getting it there on time.
☢️ BREAKING: Actinium's ATNM-400 posts first-in-human data at EANM
A non-PSMA Ac-225 shot at prostate cancer — aimed at the patients PSMA therapy leaves behind. Oral OP-525, Oct 19.
☢️ BREAKING: NorthStar expands Ac-225 access in China via Quarkmed partnership
Alpha supply goes global — Quarkmed will file NorthStar's n.c.a. Ac-225 in China INDs.
☢️ BREAKING: Lantheus shareholders approve up-to-$8B Curium merger, ~97% in favor
Radiopharma's biggest merger just cleared its biggest hurdle — regulators, you're up.
1/
I am turning this account into a breaking news wire for radiopharma and nuclear medicine. Trial readouts, FDA Decisions, deals, etc. Here's why...🧵
2/
This space is changing so quickly and growing so rapidly that my job changes every day, because the industry around me is changing. I was struggling to keep up and felt like I was the last one to know things that directly impact my company.